Back to top
more

Bioventus (BVS)

(Real Time Quote from BATS)

$13.92 USD

13.92
343,871

+0.34 (2.50%)

Updated Nov 4, 2024 02:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day.

Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

by Zacks Equity Research

PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.

Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review

by Zacks Equity Research

SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.

Insmed Stock Surges 168% in the Past Six Months: Here's Why

by Zacks Equity Research

Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.

Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids

by Zacks Equity Research

RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

by Zacks Equity Research

Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

by Zacks Equity Research

Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.

Here's Why You Should Invest in SpringWorks (SWTX) Stock Now

by Zacks Equity Research

Here, we are discussing some reasons why investing in SpringWorks (SWTX) stock now may turn out to be a prudent move.

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

by Zacks Equity Research

Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista

by Zacks Equity Research

The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

by Zacks Equity Research

A Bloomberg article suggests that Brookfield Asset Management is in discussions with banks to raise nearly $11 billion to fund the takeover of Spain-based Grifols (GRFS).

Amicus (FOLD) Banks on Galafold, High Dependence a Concern

by Zacks Equity Research

Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales. However, overdependence on Galafold for revenues remains a concern.

J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition

by Zacks Equity Research

Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million. The deal is likely to strengthen the company's MedTech business unit further.

GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

by Zacks Equity Research

Corcept, Amneal, Bioventus, Foghorn and Akebia have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy as Innovation Reaches Peak

by Kinjel Shah

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

by Zacks Equity Research

Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.

Encompass Health (EHC) Expands in Louisville With New Rehab Unit

by Zacks Equity Research

Encompass Health (EHC) and Baptist Health inaugurate a 40-bed inpatient rehabilitation hospital in Louisville, enhancing regional care and expanding EHC's network to 163 facilities.

Here's Why Investors Must Hold on to Centene (CNC) Stock Now

by Zacks Equity Research

Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.

Compelling Reasons to Hold on to Cigna (CI) Stock for Now

by Zacks Equity Research

Cigna (CI) remains well-poised for growth on the back of improved pharmacy revenues in its Evernorth unit. Solid cash-generating abilities also enable it to tactically deploy capital.

Here's Why You Should Consider Buying Bioventus (BVS) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.

J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe

by Zacks Equity Research

J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.

Humana (HUM) Partners With UAB to Boost Care for MA Members

by Zacks Equity Research

Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

by Zacks Equity Research

Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe

Merck (MRK) to Buy Private Ophthalmology Company EyeBio

by Zacks Equity Research

Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.